C. Voltz

发表

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia

C. Gisselbrecht, F. Pignatti, E. Bałkowiec-Iskra, 2021, HemaSphere.

The effects ofN-methyl-d-aspartate and kainate lesions of the rat striatum on striatal ornithine decar☐ylase activity and polyamine levels

C. Carter, D. Fage, B. Scatton, 1991, Brain Research.

Release of spermidine from the rat cortex following permanent middle cerebral artery occlusion

C. Carter, D. Fage, B. Scatton, 1995, Fundamental & clinical pharmacology.

Ouabain Releases Striatal Polyamines In Vivo Independently of N‐Methyl‐d‐Aspartate Receptor Activation

C. Carter, C. Voltz, D. Page, 1993, Journal of neurochemistry.

Implication of the polyamines in the neurotoxic effects of N-methyl-D-aspartate.

C. Carter, D. Fage, J. Bénavidès, 1992, Neurological research.

Difluoromethyl ornithine protects against the neurotoxic effects of intrastriatally administered N-methyl-D-aspartate in vivo.

C. Carter, D. Fage, B. Scatton, 1991, European journal of pharmacology.

Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent.

B. Scatton, K. Lloyd, D. Duval, 1995, Arzneimittel-Forschung.

SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (II) Efficacy in Experimental Models Predictive of Activity Against Cognitive Symptoms of Schizophrenia

G. Griebel, J. Stemmelin, O. Bergis, 2007, Neuropsychopharmacology.

Ornithine decarboxylase inhibition or NMDA receptor antagonism reduce cortical polyamine efflux associated with dialysis probe implantation

C. Carter, D. Fage, B. Scatton, 1993, Neuroscience Letters.

Selective Release of Spermine and Spermidine from the Rat Striatum by N‐Methyl‐d‐Aspartate Receptor Activation In Vivo

C. Carter, D. Fage, B. Scatton, 1992, Journal of neurochemistry.

Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012

S. Simoens, I. Huys, M. Casteels, 2017, Orphanet Journal of Rare Diseases.

The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease

C. Gisselbrecht, F. Pignatti, S. Urach, 2021, HemaSphere.

The plasma concentration of GABA shows no evidence of a circadian rhythm and is stable over weeks in normal males

K. Lloyd, R. Agosti, P. Schulz, 1994 .

Synergism between the NMDA receptor antagonistic effects of ifenprodil and the glycine antagonist, 7-chlorokynurenate, in vivo.

C. Carter, D. Fage, C. Voltz, 1994, European journal of pharmacology.

Effects of pharmacological manipulation on neurotransmitter and other amino acid levels in the CSF of the Senegalese baboonPapio papio

R. Naquet, K. Lloyd, A. Valin, 1991, Brain Research.

Characterization of the calcium and chloride [3H]glutamate binding site in crude synaptic membranes from human brain tissue.

C. Zetina, K. Lloyd, F. Vargas, 1993, General pharmacology.